Stockscreener 앱 받기
33.70
2.29%
0.74
전일 마감가:
$32.96
열려 있는:
$33.14
하루 거래량:
120.49K
Relative Volume:
0.10
시가총액:
$1.95B
수익:
$11.13M
순이익/손실:
$-105.04M
주가수익비율:
-14.93
EPS:
-2.2565
순현금흐름:
$-81.54M
1주 성능:
+3.87%
1개월 성능:
+6.43%
6개월 성능:
+436.88%
1년 성능:
+361.86%
1일 변동 폭
$32.88
$34.01
1주일 범위
$30.82
$34.64
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
33.72 | 1.91B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
427.16 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.40 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
810.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.94 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.78 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR stock in focus: Ex-exec eyed for FDA role says drug approvals are not 'best-in-class' signals - MSN
Biotech Capricor pairs Q1 results with a corporate update May 12 - Stock Titan
Capricor (NASDAQ: CAPR) EVP sells 25K shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO exercises options, sells 25,000 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - marketscreener.com
Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data ReleaseWhat's Changed - Sahm
CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%What's Next? - MarketBeat
Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
CAPR Forecast, Price Target & Analyst Ratings | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN
Understanding the Setup: (CAPR) and Scalable Risk - Stock Traders Daily
CAPR stock draws investor attention after AAN presentation for DMD therapy - MSN
Assessing Capricor Therapeutics (CAPR) Valuation After HOPE-3 Phase 3 Data And BLA Review Progress - Sahm
How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Yahoo Finance
We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn - Yahoo Finance
Roth Capital Maintains Capricor Therapeutics (CAPR) Buy Recommendation - MSN
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting - Sahm
CAPR (Capricor Therapeutics Inc.) reports wider than expected Q4 2025 loss, stock notches small gain in daily trading. - Xã Thanh Hà
CAPR (Capricor Therapeutics Inc.) reports wider Q4 2025 loss than estimates, shares dip 1.28% in today's trading.Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
CAPR (Capricor Therapeutics) EV-to-OCF : -24.77 (As of Apr. 28, 2026) - GuruFocus
Capricor Therapeutics Announces Late-Breaking Presentation - GlobeNewswire
How Investors May Respond To Capricor Therapeutics (CAPR) HOPE-3 Data and Pending FDA Decision - Sahm
Capricor (CAPR) Stock: Why Margin Expansion (Extends Gains) 2026-04-20Expert Breakout Alerts - UBND thành phố Hải Phòng
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Potential Upside of 55.83% Signals Strong Growth Potential - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Leads Healthcare Stocks with High F - GuruFocus
Capricor Therapeutics stock jumps as FDA resumes Deramiocel review - MSN
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x (XLV:NYSEARCA) - Seeking Alpha
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6% - MarketBeat
The Technical Signals Behind (CAPR) That Institutions Follow - Stock Traders Daily
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Capricor's Former Executive Considered for FDA Biologics Chief - Intellectia AI
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.7%Should You Buy? - MarketBeat
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
[ARS] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics | DEF 14A: Definitive information statements - Moomoo
Capricor Therapeutics (NASDAQ: CAPR) details 2026 meeting, board elections, pay and Deramiocel deals - Stock Titan
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Aug Update: Is Capricor Therapeutics Inc stock a value trapMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - The Chronicle-Journal
JPMorgan Chase Reduces Stake in Capricor Therapeutics - National Today
JPMorgan Chase & Co. Decreases Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Aug PreEarnings: Whats the profit margin of Capricor Therapeutics IncQuarterly Profit Summary & Consistent Income Trade Ideas - baoquankhu1.vn
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
3.01%
자본화:
|
볼륨(24시간):